25 min listen
The Promising Field of Targeted Protein Degraders (TPDs)
The Promising Field of Targeted Protein Degraders (TPDs)
ratings:
Length:
23 minutes
Released:
Jul 30, 2022
Format:
Podcast episode
Description
with Back Bay Life Science Advisors’ Dr. Peter Bak and Dr. Mavra NasirDr. Mavra Nasir recently published a thought piece in Biopharma Dealmakers outlining the current state of play in the promising field of protein degradation. In this episode, Dr. Nasir sits down with Peter Bak to discuss the recent surge of venture funding and partnerships surrounding TPDs.Read Dr. Nasir's article "From drug target inhibition to degradation: a TACtical strategy" here. Topics in this podcast include:
An intro into targeted protein degradation (TPDs) and proteolysis-targeting chimeras (PROTACs)
Industry advantages of TPDs vs. traditional antibodies
Biopharma and VC's growing interest in molecular glues
Commercial hurdles ahead in this space
How TPD companies can differentiate, from a pipeline and breadth of opportunities to select an indication, communicate to investors and drive value
If you have a question about life sciences development, submit it here. We may feature it on an upcoming episode.Thanks for joining us!*Mavra Nasir, PhD is a senior consultant at Back Bay Life Science Advisors where she supports strategic engagements across a range of therapeutic areas including rare diseases, hematology/oncology and metabolic diseases for biopharma and MedTech. Dr. Nasir joined Back Bay after receiving her PhD in Quantitative Biomedical Sciences from Dartmouth College.
An intro into targeted protein degradation (TPDs) and proteolysis-targeting chimeras (PROTACs)
Industry advantages of TPDs vs. traditional antibodies
Biopharma and VC's growing interest in molecular glues
Commercial hurdles ahead in this space
How TPD companies can differentiate, from a pipeline and breadth of opportunities to select an indication, communicate to investors and drive value
If you have a question about life sciences development, submit it here. We may feature it on an upcoming episode.Thanks for joining us!*Mavra Nasir, PhD is a senior consultant at Back Bay Life Science Advisors where she supports strategic engagements across a range of therapeutic areas including rare diseases, hematology/oncology and metabolic diseases for biopharma and MedTech. Dr. Nasir joined Back Bay after receiving her PhD in Quantitative Biomedical Sciences from Dartmouth College.
Released:
Jul 30, 2022
Format:
Podcast episode
Titles in the series (27)
Life Science SPACs: A Forward Look at this Evolving Asset Class: In this week’s episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, is joined by Gregory Benning and Vasilios Kofitsas of Back Bay’s investment banking team to talk about the market of Special Purpose Acquisition Companies (SPACs). by Back Bay Life Science Report